2002
DOI: 10.1002/ajh.1192
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic choices for patients with hemophilia and high‐titer inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
58
0
2

Year Published

2002
2002
2017
2017

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 39 publications
(60 citation statements)
references
References 0 publications
0
58
0
2
Order By: Relevance
“…20 On the other hand, the management of hemophilia with inhibitors is particularly expensive, both in absolute terms and in comparison with the treatment of hemophilia without inhibitors. 21 Available studies on costs and quality of life are retrospective, often carried out in single centers on very small numbers of patients, and focused mainly on drug costs. 4,5 No prospective study has specifically focused on patients with hemophilia and inhibitors with the objective of assessing the global socioeconomic and cultural impact of management.…”
Section: Introductionmentioning
confidence: 99%
“…20 On the other hand, the management of hemophilia with inhibitors is particularly expensive, both in absolute terms and in comparison with the treatment of hemophilia without inhibitors. 21 Available studies on costs and quality of life are retrospective, often carried out in single centers on very small numbers of patients, and focused mainly on drug costs. 4,5 No prospective study has specifically focused on patients with hemophilia and inhibitors with the objective of assessing the global socioeconomic and cultural impact of management.…”
Section: Introductionmentioning
confidence: 99%
“…Interestingly, porcine FVIII has been used effectively in the clinic as a "bypass" therapy; that is, a therapeutic protein that can evade neutralization by anti-FVIII antibodies in many allo-and autoimmune inhibitor patients. [5][6][7] However, some patients have or could develop antibodies that neutralize porcine FVIII as well, 8 because of antigenic cross-reactivity 9 or because regions in which the porcine sequence differs from the human FVIII sequence stimulate effector T cells, leading to antibody production. Identification of the binding sites (B-cell epitopes) on FVIII that are recognized by inhibitors would allow rational design of novel therapeutic FVIII proteins that are more similar to human FVIII and, hence, likely to be less immunogenic.…”
Section: Introductionmentioning
confidence: 99%
“…Of particular concern are Abs that may render the drugs less effective; examples include the development of Abs against factor VIII in hemophiliacs (1,2), calcitonin in patients treated for osteoporosis (3,4), erythropoietin (Epo) 2 in patients undergoing therapy for chronic renal failure (5,6), and IFN-␤ in individuals undergoing treatment for multiple sclerosis (7).…”
mentioning
confidence: 99%